Inactive Instrument

Mallinckrodt plc

MNK

IE000O3L0NQ3

Mallinckrodt plc announced that it has received €0.04 million in funding.

January 11, 2013 at 09:30 am IST

Mallinckrodt plc (NYSE:MNK) announced a private placement of 40,000 ordinary A shares at €1 per share for gross proceeds of €40,000 to an Irish corporate services provider on January 11, 2013.

On January 11, 2013, Mallinckrodt plc closed the transaction.

Latest news about Mallinckrodt plc

Mallinckrodt plc Presents Data on Terlipressin for Injection in Patients with Hepatorenal Syndrome at the 2024 European Association for the Study of the Liver Congress	05/06	CI
Mallinckrodt plc Presents Data on TERLIVAZ® (terlipressin) for Injection in Patients with Hepatorenal Syndrome at the 2024 Digestive Disease Week®	18/05	CI
Mallinckrodt plc Reports Earnings Results for the First Quarter Ended March 29, 2024	09/05	CI
Mallinckrodt plc Reaffirms Financial Guidance for the Full Year of 2024	09/05	CI
Mallinckrodt plc Reports Earnings Results for the Full Year Ended December 29, 2023	27/03	CI
Mallinckrodt plc Reports Earnings Results for the Fourth Quarter Ended December 29, 2023	27/03	CI
Mallinckrodt plc Provides Earnings Guidance for the Year 2024	27/03	CI
Mallinckrodt Appoints Paul O'neill as Executive Vice President, Quality & Operations, Specialty Brands	04/03	CI
Mallinckrodt plc Announces FDA Clearance of the INOmax® EVOLVE? DS Delivery System and Approval of the INOmax® Mini-Cylinder	08/12	CI
Mallinckrodt plc Announces Resignation of Sigurdur Olafsson as Chief Executive Officer	15/11	CI
Mallinckrodt plc Announces Board Changes	15/11	CI
Drugmaker Mallinckrodt emerges from bankruptcy	15/11	RE
Drugmaker Mallinckrodt emerges from bankruptcy	15/11	RE
Mallinckrodt plc Emerged from Bankruptcy	14/11	CI
Mallinckrodt plc to Present Breadth of Data on Terlivaz (Terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome At the American Association for the Study of Liver Diseases 2023 Liver Meeting	08/11	CI
Mallinckrodt plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 29, 2023	07/11	CI
Mallinckrodt plc Revises Earnings Guidance for the Full-Year of 2023	07/11	CI
Mallinckrodt Presents Latest Health Economics Data on Acthar Gel (Repository Corticotropin Injection) At the Academy of Managed Care Pharmacy Nexus 2023	26/23/26	CI
Rite Aid joins companies going bankrupt amid opioid litigation	16/23/16	RE
Drug retailer Rite Aid files for bankruptcy, gets $3.45 bln commitment	16/23/16	RE
U.S. Inflation Might Settle Above Target; Fed Is -2-	13/23/13	DJ
Mallinckrodt gets court approval for restructuring, $1 bln cut to opioid settlement	10/23/10	RE
MALLINCKRODT GETS COURT APPROVAL FOR RESTRUCTURING, $1 BLN CUT T…	10/23/10	RE
Mallinckrodt Announces Publication of Two Journal Manuscripts with Clinical and Economic Evidence for Acthar Gel (Repository Corticotropin Injection)	10/23/10	CI
First Amended Reorganization Plan Approved for Mallinckrodt plc	10/23/10	CI

Chart Mallinckrodt plc

Duration

Period

More charts

Company Profile

Mallinckrodt plc develops, manufactures, markets, and distributes branded and generic specialty pharmaceutical products and therapies. The Company operates in two reportable segments: Specialty Brands and Specialty Generics. The Specialty Brands includes specialty pharmaceutical brands. The Specialty Generics includes niche specialty generic drugs and active pharmaceutical ingredients. Its Specialty Generics segment is focused on providing its customers with specialty generic drugs and active pharmaceutical ingredients (APIs). The Company focuses on various therapeutic areas, such as autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics, cultured skin substitutes and gastrointestinal products. Its product portfolio includes Acthar Gel, INOmax, Therakos photopheresis, StrataGraft, Terlivaz, and Amitiza.

Sector

Pharmaceuticals

Calendar

06/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+55.35%	815B
NOVO NORDISK A/S	+32.04%	597B
JOHNSON & JOHNSON	-0.10%	377B
MERCK & CO., INC.	+15.47%	319B
ABBVIE INC.	+13.10%	310B
ROCHE HOLDING AG	+12.76%	250B
ASTRAZENECA PLC	+16.32%	247B
AMGEN INC.	+16.54%	180B
PFIZER, INC.	+4.31%	170B

Other Pharmaceuticals